{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:26Z","timestamp":1790983166680,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Osimertinib is recommended not only for advanced EGFR-mutated non-small cell lung cancer (NSCLC) but also as adjuvant therapy after complete resection, leading to increasing opportunities for its clinical use. However, interstitial lung disease (ILD) is a serious adverse event, and its incidence and severity have been reported to be higher in Japanese patients. We report a fatal case of osimertinib-related ILD that developed during adjuvant therapy in a patient undergoing maintenance hemodialysis after left pneumonectomy. A 71-year-old man was found to have a left upper lobe mass on chest computed tomography (CT) performed at the initiation of maintenance hemodialysis for nephrosclerosis. Transbronchial biopsy was nondiagnostic; however, lung cancer was strongly suspected clinically, and video-assisted thoracoscopic left pneumonectomy with mediastinal lymph node dissection was performed. Pathological examination revealed lung adenocarcinoma harboring an EGFR exon 19 deletion, pT2aN2bM0 (stage IIIB). Adjuvant osimertinib (80 mg\/day) was initiated. Exertional dyspnea developed 37 days after treatment initiation, and chest CT on day 40 revealed peripheral ground-glass opacities in the remaining right lung. Osimertinib was discontinued, and empirical antibiotic therapy was initiated because both osimertinib-related ILD and infection were considered in the differential diagnosis. Shortly after admission, the patient developed rapidly progressive respiratory failure. Although steroid pulse therapy led to temporary improvement, the respiratory status deteriorated again, and the patient died on day 57 after osimertinib initiation despite an additional course of steroid pulse therapy. This case highlights that osimertinib-related ILD can become fatal not only in advanced or recurrent disease but also during curative-intent adjuvant therapy. Careful monitoring and prompt evaluation and intervention are particularly important in patients with poor respiratory reserve.<\/jats:p>","DOI":"10.3389\/fonc.2026.1860840","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:24:55Z","timestamp":1785126295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Fatal osimertinib-related interstitial lung disease during adjuvant therapy after left pneumonectomy in a patient with lung adenocarcinoma undergoing maintenance hemodialysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Takahiro","family":"Kaki","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Harutani","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University","place":["Wakayama, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Breast and General Thoracic Surgery, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Breast and General Thoracic Surgery, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Wakayama Medical University","place":["Wakayama, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tsuchihashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuninobu","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Naga Municipal Hospital","place":["Kinokawa, Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","unstructured":"Lung Cancer Clinical Practice Guidelines 2025: non-Small Cell Lung Cancer\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.05.035","article-title":"Drug-related pneumonitis induced by osimertinib as first-line treatment for epidermal growth factor receptor mutation-positive non-small cell lung cancer: a real-world setting","volume":"162","author":"Sato","year":"2022","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"B8","unstructured":"Tagrisso Tablets 40 Mg and 80 Mg: Risk Management Plan. Pharmaceuticals and Medical Devices Agency"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100631","article-title":"Severe drug-induced interstitial lung disease after administration of osimertinib as adjuvant treatment for resected EGFR-mutated NSCLC: a case report","volume":"5","author":"Mitsuya","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.21037\/acr-24-203","article-title":"Life-threatening interstitial lung disease with adjuvant osimertinib after complete resection of non-small cell lung cancer: a case report","volume":"9","author":"Osako","year":"2025","journal-title":"AME Case Rep"},{"key":"B11","unstructured":"Geneva\n          World Health Organization\n          The Use of the WHO-UMC System for Standardised Case Causality Assessment\n          \n          2013"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1345","article-title":"Evaluation of expiratory volume, diffusion capacity, and exercise tolerance following major lung resection: a prospective follow-up analysis","volume":"131","author":"Brunelli","year":"2007","journal-title":"Chest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1052-3359(25)00433-8","article-title":"Morbidity and mortality after pneumonectomy","volume":"9","author":"Klemperer","year":"1999","journal-title":"Chest Surg Clin N Am"},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cllc.2025.09.014","article-title":"Late survival and hospital trajectory after pneumonectomy for non-small cell lung cancer","volume":"27","author":"Daffre","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00851-y","article-title":"Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report","volume":"38","author":"Matsunashi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.007","article-title":"Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis","volume":"112","author":"Tamura","year":"2017","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-2992-z","article-title":"Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies","volume":"77","author":"Planchard","year":"2016","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1860840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:24:58Z","timestamp":1785126298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1860840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1860840"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1860840","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1860840"}}